lncRNA 430945 promotes VSMC proliferation and migration. (A) VSMCs were transfected with pcDNA or pcDNA-lncRNA430945 for 24 h and the expression of lncRNA 430945 was analyzed by quantitative polymerase chain reaction analysis. *P<0.05, vs. control (n=3). (B) VSMC monolayers were pre-treated with pcDNA or pcDNA-lncRNA430945 for 24 h prior to being wounded, and cells migrating to the scratch gap were quantified (magnification, ×100). The data are presented as the mean ± standard deviation from three independent experiments. *P<0.05, vs. pcDNA. (C) Cell growth was assessed using a cell viability Cell Counting Kit-8 assay following transfection with pcDNA or pcDNA-lncRNA430945 for 0, 12, 24, 36 and 48 h. *P<0.05 and **P<0.01 vs. pcDNA at different times (n=3). (D) Representative photomicrographs of a Transwell assay showing the quantification of VSMC invasion (magnification, ×400). The number of invaded cells was measured in three separate experiments and data represent the mean ± standard deviation (n=3). *P<0.05, vs. pcDNA group. (E) VSMCs were transfected with pcDNA or pcDNA-lncRNA430945 for 24 h and total cell lysates were analyzed by western blotting with anti-ROR2 antibody. *P<0.05, vs. pcDNA (n=3). VSMCs, vascular smooth muscle cells; ROR2, receptor tyrosine kinase-like orphan receptor 2; lncRNAs, long non-coding RNAs.